Nov 7, 2022 MDimune, Inc. announced a business agreement with EUMC and acquisition of IP from EUMC to develop therapeutics for inflammatory bowel diseases (IBD).
Oct 24, 2022 MDimune, Inc. enters into an MOU with SensoryCure to collaborate on the development of therapeutics for hearing loss .
Sep 15, 2022 Caravan Biologix and MDimune announced their collaboration to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers.
May 2022 A distinguished panel and the editorial board of Life Science Review APAC has selected a list of biotech startups. MDimune: The Pioneer of Cell-Derived-Vesicle Therapeutics
Feb 28, 2022 MDimune has announced the joint research agreement with YiPSCELL to develop BioDrone® Platform therapeutics based on induced pluripotent stem cells (iPSCs).
Jan 5, 2022 PCI (Oslo, Norway) and MDmune today announced a preclinical research collaboration that would offer several opportunities for future development.
Dec 28, 2021 Among participants, Assoc. Prof. Giorgia Pastorin’s BioNanoTechnology Research Group at the National University of Singapore’s Department of Pharmacy (NUS Pharmacy) was nominated as the finalist of the program.
Oct 29, 2021 MDimune and Kainos Medicine have inked a collaboration and possible licensing deal for cancer therapy development based on CDVs loaded with Fas-associated Factor 1 (FAF1) expressing mRNA or protein.
Oct 22, 2021 NeoCura Bio-Medical Technology Co., Ltd, a leading AI-enabled RNA precision medicine company and MDimune Inc. have announced the signing of collaboration focused on mRNA delivery for oncological therapeutics.
Sep 13, 2021 MDimune Inc., a leading cell-derived vesicles (CDVs) company in South Korea has announced the outcomes of the research collaboration with Prof. Joonghoon Park’s team at Seoul National University.
Sep 9, 2021 This collaboration with top-ranked university in South Korea will revolutionize the delivery of gene editing nuclease packaged CDVs for precise delivery to cells which will enable gene correction, gene modification, knockout and gene addition at intended location.
Sep 7, 2021 MDimune Inc. and Vect-Horus are please to announce today the signing of a Research Collaboration Agreement.
Aug 26, 2021 International Business Times discusses exosome research and introduces pace-setting companies.
May 13, 2021 Reyon and MDimune has announced the signing of a partnership focused on mRNA delivery for antivirus vaccine and rare genetic disorder.
May 11, 2021 Navigo Proteins and MDimune announced a technology collaboration to achieve tissue-targeting of extracellular vesicles (EVs), Affilin®-mediated delivery of CDVs specifically to solid tumor targets.
Apr 5, 2021 MDimune and Evercyte GmbH announced a strategic collaboration to develop tumor-targeted drug delivery by combining their technologies.
Mar 15, 2021 ExonanoRNA and MDimune have entered into a service agreement to develop targeted siRNA therapy in oncology applications.
Oct 30, 2020 MDimune announced the signing of research agreements with Pohang University of Science and Technology (POSTECH), Konkuk University, and Catholic University.
Oct 28, 2020 Plug and Play, headquartered in Silicon Valley, California, announced that MDimune will be partnering with Lonza. MDimune is among 11 Batch 5 startups to join the global startup incubation program ‘Startup Creasphere’.
Oct 26, 2020 BioDrone® platform technology was awarded the “Best Cell Therapy Technology of the Year” at the annual Cell Therapy World Asia 2020 conference.
Apr 30, 2020 MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development.
Apr 8, 2020 MDimune Received U.S. Patent on BioDrone® Technology.